LETICIA DE MATTOS-ARRUDA


Current positions

  • Junior Principal Investigator, VHIO´s Applied Genetics of Metastatic Cancer Group
  • Active member of the European Society of Medical Oncology´s (ESMO) Young Oncologist Committee (YOC).
  • President of the FLIMS Alumni Club of the ECCO – AACR – EORTC – ESMO Workshop on Methods in Clinical Cancer Research (an advisory member of ECCO – the European CanCer Organisation).
  • Active member of the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Association of Cancer Research (EACR).

Academic Qualifications

  • 2004 – Medical Doctor Degree. Belo Horizonte, MG, Brazil.
  • 200 – Medical Oncology. Belo Horizonte, MG, Brazil.
  • 2009-2013 – Clinical Research Fellowship: Vall d’Hebron Institute of Oncology/University Hospital, Barcelona, Spain (Breast Cancer and Phase 1 Units).
  • 2010 – Board Certified in Medical Oncology, European Society of Medical Oncology, ESMO Examination, Milan, Italy.
  • 2012-2016 – Laboratory member, VHIO´s Gene Expression and Cancer Group headed by Joan Seoane.
  • 2012-2013 – Masters: Universitat Autònoma de Barcelona, Barcelona, Spain.
  • 2013-2016 – PhD in Medicine: Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Excellent Cum Laude.
  • 2014-201 – Visiting Research Fellow, Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA (Jorge Reis-Filho´s Laboratory).
  • 2015-2017 – Visiting Research Scientist, Cancer Research UK – Cambridge Institute, University of Cambridge (Carlos Caldas´ Laboratory).

Areas of Research

  • Tumour heterogeneity, multi-omics, immune-genomics, metastatic breast cancer, brain metastasis, plasma and cerebrospinal fluid cell-free tumour DNA, applied bioinformatics analyses.

Prizes and Scholarships

  • 2009 – International Development and Education Award (IDEA) of ASCO Cancer Foundation, American Society of Clinical Oncology, Orlando, Florida, US. Visiting fellow: USC University of Southern California, US.
  • 2009 – Translational Research Unit Visit Fellowship of ESMO – European Society for Medical Oncology. Institute Jules Bordet, Brussels, Belgium.
  • 2010 – 12o ECCO – AACR – EORTC – ESMO Methods in Clinical Cancer Research. Special grant: Ontario Institute of Cancer Research. Flims, Switzerland.
  • 2010-201 – ESMO Translational Research Fellowship Grant.
  • 2012 – Susan G. Komen for the Cure® travel grant. IMPAKT Breast Cancer Conference,  Brussels, Belgium.
  • 2012 – Merit Award of ASCO Conquer Cancer Foundation, American Society of Clinical Oncology, Chicago, USA.
  • 2012 – ESMO travel grant, European Society for Medical Oncology, Vienna, Austria.
  • 2013 – Merit Award of ASCO Conquer Cancer Foundation, American Society of Clinical Oncology, Chicago, USA.
  • 2013 – AACR Scholar-In-Training Award, San Antonio Breast Cancer Symposium, San Antonio, TX, USA.
  • 2014/2015 – Advanced Program in Oncology awarded by the Asociación Español Contra el Cáncer (AECC) for tenure at CRUK – Cambridge Institute.
  • 2017 – ESMO Leaders Generation Program, Lugano, Switzerland.

Most relevant scientific publications

  • De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortes J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016; 13(9): 566-79.
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martinez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martinez-Saez E, Lois S, Marin O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, Gonzalez-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839.
  • De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol 2016; 10(3): 464-74.
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25(9): 1729-35.
  • De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013; 10(7): 377-89.

All publications

  • De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortes J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016; 13(9): 566-79.
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martinez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martinez-Saez E, Lois S, Marin O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, Gonzalez-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839.
  • De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol 2016; 10(3): 464-74.
  • Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). ESMO Open 2016; 1(6):e000107.
  • Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS. The Genomic Landscape of Male Breast Cancers. Clin Cancer Res 2016; 22(16): 4045-56.
  • Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 2015; 112(4): 650-9.
  • Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchio C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. J Pathol 2015; 237(2): 166-78.
  • Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Munoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res 2015; 25(6): 486-95.
  • Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, Edelweiss M, De Mattos-Arruda L, Wen HY, Rakha EA, Ellis IO, Rubin BP, Weigelt B, Reis-Filho JS. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015; 67(4): 529-37.
  • De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Perez-Garcia J, Masci G, Corsi F, Cortes J, Seoane J, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015; 6(35): 37269-80.
  • Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med 2014; 276(1): 41-51.
  • Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol 2014; 8(6): 1120-31.
  • Seoane J, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov 2014; 4(11): 1259-61.
  • Ramon YCS, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin Transl Oncol 2014; 16(11): 937-41.
  • Piscuoglio S, Ng CK, Martelotto LG, Eberle CA, Cowell CF, Natrajan R, Bidard FC, De Mattos-Arruda L, Wilkerson PM, Mariani O, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol 2014; 8(8): 1588-602.
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25(9): 1729-35.
  • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2014; 8(1): 150-8.
  • Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014; 15(4): 406-14.
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013; 3(11): 1238-44.
  • Oliveira M, Cortes J, Bellet M, Balmana J, De Mattos-Arruda L, Gomez P, Munoz E, Ortega V, Perez J, Saura C, Vidal M, Rubio IT, Di Cosimo S. Management of the axilla in early breast cancer patients in the genomic era. Ann Oncol 2013; 24(5): 1163-70.
  • Di Cosimo S, De Mattos-Arruda L, Rubio I, Cortes J. Re: time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. J Natl Cancer Inst 2013; 105(24): 1912.
  • De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 2013; 18(11): 1180-8.
  • De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013; 10(7): 377-89.
  • De Mattos-Arruda L, Cortes J. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. Adv Ther 2013; 30(7): 645-58.
  • Azim HA, Jr., Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31(1): 73-9.
  • Serrano C, Cortes J, De Mattos-Arruda L, Bellet M, Gomez P, Saura C, Perez J, Vidal M, Munoz-Couselo E, Carreras MJ, Sanchez-Olle G, Tabernero J, Baselga J, Di Cosimo S. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23(4): 897-902.
  • De Mattos-Arruda L, Tabernero J, Seoane J, Cortes J. Circulating tumour cells in early breast cancer. Lancet Oncol 2012; 13(9): e370; author reply e.
  • De Mattos-Arruda L, Cortes J. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist 2012; 17(5): 631-44.
  • De Mattos-Arruda L, Cortes J. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype? Breast 2012; 21(4): 604-7.
  • Cortes J, Calvo E, Gonzalez-Martin A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gomez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol 2012; 30(28): 3444-7.
  • De Mattos-Arruda L, Olmos D, Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol 2011; 7(12): 1385-97.
  • De Mattos-Arruda L, Elattar I, Azim HA, Jr. Circulating tumor cells in metastatic breast cancer: the need for a standardized approach. Ann Oncol 2011; 22(1): 234.
  • De Mattos-Arruda L, Dienstmann R, Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer 2011; 10(4): 279-89.

BOOK CHAPTERS

  • De Mattos-Arruda L, Preusser, M. ESMO handbook of Oncological Emergencies: Complications of brain metastases. 2016
  • De Mattos-Arruda L, Cortes J. HER2-positive metastatic breast cancer: first-line treatment. Handbook of HER2-targeted agents in breast cancer. 2016 (Update version)
  • De Mattos-Arruda L, Weigelt B, Reis-Filho JS. Genomic Applications in Breast Carcinoma. 2014
  • De Mattos-Arruda L, Cortes J. HER2-positive metastatic breast cancer: first-line treatment. Handbook of HER2-targeted agents in breast cancer. 2013